NVS Stock Recent News

Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.

Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation, supportive dividend yield, and ongoing buyback make it a buy. The company also trades below its peer average multiple.

Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield.

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion.

Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.

Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive.